Next Article in Journal
Molecular Mechanism and Application of Somatic Cell Cloning in Mammals—Past, Present and Future
Next Article in Special Issue
SP600125 Enhances Temperature-Controlled Repeated Thermal Stimulation-Induced Neurite Outgrowth in PC12-P1F1 Cells
Previous Article in Journal
TFG-β Nuclear Staining as a Potential Relapse Risk Factor in Early-Stage Non-Small-Cell Lung Cancer
Previous Article in Special Issue
Control of Expression of Key Cell Cycle Enzymes Drives Cell Line-Specific Functions of CDK7 in Human PDAC Cells
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 23
Issue 22
10.3390/ijms232213784
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas

by
Víctor Albarrán
*,
María Luisa Villamayor
,
Jesús Chamorro
,
Diana Isabel Rosero
,
Javier Pozas
,
María San Román
,
Juan Carlos Calvo
,
Patricia Pérez de Aguado
,
Jaime Moreno
,
Patricia Guerrero
,
Carlos González
,
Coral García de Quevedo
,
Pablo Álvarez-Ballesteros
and
María Ángeles Vaz
Department of Medical Oncology, Ramon y Cajal University Hospital, 28034 Madrid, Spain
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2022, 23(22), 13784; https://doi.org/10.3390/ijms232213784
Submission received: 6 October 2022 / Revised: 5 November 2022 / Accepted: 7 November 2022 / Published: 9 November 2022
(This article belongs to the Special Issue Kinase Signal Transduction 3.0)
Browse Figure
Review Reports Versions Notes

Abstract

Bone sarcomas are a heterogeneous group of rare tumors with a predominance in the young population. Few options of systemic treatment are available once they become unresectable and resistant to conventional chemotherapy. A better knowledge of the key role that tyrosine kinase receptors (VEGFR, RET, MET, AXL, PDGFR, KIT, FGFR, IGF-1R) may play in the pathogenesis of these tumors has led to the development of multi-target inhibitors (TKIs) that are progressively being incorporated into our therapeutic arsenal. Osteosarcoma (OS) is the most frequent primary bone tumor and several TKIs have demonstrated clinical benefit in phase II clinical trials (cabozantinib, regorafenib, apatinib, sorafenib, and lenvatinib). Although the development of TKIs for other primary bone tumors is less advanced, preclinical data and early trials have begun to show their potential benefit in advanced Ewing sarcoma (ES) and rarer bone tumors (chondrosarcoma, chordoma, giant cell tumor of bone, and undifferentiated pleomorphic sarcoma). Previous reviews have mainly provided information on TKIs for OS and ES. We aim to summarize the existing knowledge regarding the use of TKIs in all bone sarcomas including the most recent studies as well as the potential synergistic effects of their combination with other systemic therapies.
Keywords: tyrosine kinase receptors; TKI; target; osteosarcoma; Ewing sarcoma; chondrosarcoma; chordoma tyrosine kinase receptors; TKI; target; osteosarcoma; Ewing sarcoma; chondrosarcoma; chordoma

Share and Cite

MDPI and ACS Style

Albarrán, V.; Villamayor, M.L.; Chamorro, J.; Rosero, D.I.; Pozas, J.; San Román, M.; Calvo, J.C.; Pérez de Aguado, P.; Moreno, J.; Guerrero, P.; et al. Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas. Int. J. Mol. Sci. 2022, 23, 13784. https://doi.org/10.3390/ijms232213784

AMA Style

Albarrán V, Villamayor ML, Chamorro J, Rosero DI, Pozas J, San Román M, Calvo JC, Pérez de Aguado P, Moreno J, Guerrero P, et al. Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas. International Journal of Molecular Sciences. 2022; 23(22):13784. https://doi.org/10.3390/ijms232213784

Chicago/Turabian Style

Albarrán, Víctor, María Luisa Villamayor, Jesús Chamorro, Diana Isabel Rosero, Javier Pozas, María San Román, Juan Carlos Calvo, Patricia Pérez de Aguado, Jaime Moreno, Patricia Guerrero, and et al. 2022. "Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas" International Journal of Molecular Sciences 23, no. 22: 13784. https://doi.org/10.3390/ijms232213784

APA Style

Albarrán, V., Villamayor, M. L., Chamorro, J., Rosero, D. I., Pozas, J., San Román, M., Calvo, J. C., Pérez de Aguado, P., Moreno, J., Guerrero, P., González, C., García de Quevedo, C., Álvarez-Ballesteros, P., & Vaz, M. Á. (2022). Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas. International Journal of Molecular Sciences, 23(22), 13784. https://doi.org/10.3390/ijms232213784

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop